Insider Spends ₹9.0m Buying More Shares In Marksans Pharma

Potential Marksans Pharma Limited (NSE:MARKSANS) shareholders may wish to note that the Whole-time Director, Sandra Saldanha, recently bought ₹9.0m worth of stock, paying ₹141 for each share. That's a very solid buy in our book, and increased their holding by a noteworthy 24%.

View our latest analysis for Marksans Pharma

Marksans Pharma Insider Transactions Over The Last Year

In fact, the recent purchase by Sandra Saldanha was the biggest purchase of Marksans Pharma shares made by an insider individual in the last twelve months, according to our records. We do like to see buying, but this purchase was made at well below the current price of ₹158. While it does suggest insiders consider the stock undervalued at lower prices, this transaction doesn't tell us much about what they think of current prices.

Sandra Saldanha bought 110.28k shares over the last 12 months at an average price of ₹143. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

There are always plenty of stocks that insiders are buying. If investing in lesser known companies is your style, you could take a look at this free list of companies. (Hint: insiders have been buying them).

Does Marksans Pharma Boast High Insider Ownership?

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. We usually like to see fairly high levels of insider ownership. Marksans Pharma insiders own about ₹31b worth of shares (which is 44% of the company). I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.

So What Does This Data Suggest About Marksans Pharma Insiders?

It is good to see the recent insider purchase. And the longer term insider transactions also give us confidence. When combined with notable insider ownership, these factors suggest Marksans Pharma insiders are well aligned, and quite possibly think the share price is too low. Looks promising! In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Marksans Pharma. Case in point: We've spotted 2 warning signs for Marksans Pharma you should be aware of, and 1 of them doesn't sit too well with us.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.